» Articles » PMID: 25635035

Metabolically Healthy Obesity and Risk of Incident CKD

Overview
Specialty Nephrology
Date 2015 Jan 31
PMID 25635035
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Metabolically healthy obesity (MHO) is a unique obesity phenotype that apparently protects people from the metabolic complications of obesity. The association between MHO phenotype and incident CKD is unclear. Thus, this study investigated the association between MHO phenotype and incident CKD.

Design, Setting, Participants, & Measurements: A total of 3136 Japanese participants were enrolled in an 8-year follow-up cohort study in 2001. Metabolically healthy status was assessed by common clinical markers: BP, triglycerides, HDL cholesterol, and fasting plasma glucose concentrations. Body mass index ≥25.0 kg/m(2) was defined as obesity. CKD was defined by proteinuria or eGFR of <60 ml/min per 1.73 m(2). To calculate the odds ratio for incident CKD, logistic regression analyses were performed.

Results: The crude incidence proportions of CKD were 2.6% (56 of 2122 participants) in participants with the metabolically healthy nonobesity phenotype, 2.6% (8 of 302) in those with the MHO phenotype, 6.7% (30 of 445) in those with the metabolically abnormal nonobesity phenotype, and 10.9% (29 of 267) in those with the metabolically abnormal obesity phenotype. Compared with metabolically healthy nonobesity phenotype, the odds ratios for incident CKD were 0.83 (95% confidence interval [95% CI], 0.36 to 1.72; P=0.64) for MHO, 1.44 (95% CI, 0.80 to 2.57; P=0.22) for metabolically abnormal nonobesity, and 2.80 (95% CI, 1.45 to 5.35; P=0.02) for metabolically abnormal obesity phenotype after adjustment for confounders, including age, sex, smoking statues, alcohol use, creatinine, uric acid, systolic BP, HDL cholesterol, and impaired fasting glucose or diabetes.

Conclusion: MHO phenotype was not associated with higher risk of incident CKD.

Citing Articles

The risk of kidney dysfunction in metabolically healthy/unhealthy population with normal weight or overweight/obesity: a systematic review and meta-analysis.

Valizadeh M, Ahmadi A, Abbaspour F, Valizadeh A, Syed Hasani A, Moteshakereh S Eat Weight Disord. 2024; 29(1):69.

PMID: 39487860 PMC: 11531429. DOI: 10.1007/s40519-024-01697-x.


Causality of visceral adipose tissue on chronic kidney disease and renal function measure indicators, and mediation role of hypertension: Mendelian randomization study.

Gao T, Wang J, Zhao Q, Zhou X, Jiang Y, Ren L Obes Rev. 2024; 26(2):e13845.

PMID: 39390683 PMC: 11711081. DOI: 10.1111/obr.13845.


Metabolic Risk Profile and Graft Function Deterioration 2 Years After Kidney Transplant.

Yan J, Yang X, Wang J, Cai H, Che X, Ying L JAMA Netw Open. 2023; 6(12):e2349538.

PMID: 38150251 PMC: 10753396. DOI: 10.1001/jamanetworkopen.2023.49538.


Obesity Patterns, Metabolic Abnormality, and Diabetic Kidney Disease in Patients with Type 2 Diabetes.

Zhang K, Zhang W, Xia F, Wang N, Lu Y, Sui C Diabetes Metab Syndr Obes. 2023; 16:3999-4011.

PMID: 38089429 PMC: 10712678. DOI: 10.2147/DMSO.S436046.


Metabolic health status and renal disorders: a cross-sectional study.

Moeinzadeh F, Rouhani M, Seirafian S, Vahdat S, Mortazavi M, Clark C Sci Rep. 2023; 13(1):20794.

PMID: 38012254 PMC: 10682426. DOI: 10.1038/s41598-023-48333-9.


References
1.
Adamczak M, Wiecek A . The adipose tissue as an endocrine organ. Semin Nephrol. 2013; 33(1):2-13. DOI: 10.1016/j.semnephrol.2012.12.008. View

2.
Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P . Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr. 2010; 64(10):1043-51. DOI: 10.1038/ejcn.2010.114. View

3.
Gansevoort R, Correa-Rotter R, Hemmelgarn B, Jafar T, Lambers Heerspink H, Mann J . Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382(9889):339-52. DOI: 10.1016/S0140-6736(13)60595-4. View

4.
Kramer C, Zinman B, Retnakaran R . Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013; 159(11):758-69. DOI: 10.7326/0003-4819-159-11-201312030-00008. View

5.
Roberson L, Aneni E, Maziak W, Agatston A, Feldman T, Rouseff M . Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. BMC Public Health. 2014; 14:14. PMC: 3890499. DOI: 10.1186/1471-2458-14-14. View